Back to Search Start Over

Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients' and clinicians' perspectives after a 12-month randomized controlled trial

Authors :
Peter Blanken
Maartje Schermer
Ernst L. Noordraven
Cornelis L. Mulder
André I. Wierdsma
Public Health
Psychiatry
Source :
BMC Psychiatry, 17:313. BioMed Central Ltd., BMC Psychiatry, Vol 17, Iss 1, Pp 1-8 (2017), BMC Psychiatry
Publication Year :
2017
Publisher :
BioMed Central Ltd., 2017.

Abstract

Background A randomized controlled trial ‘Money for Medication’(M4M) was conducted in which patients were offered financial incentives for taking antipsychotic depot medication. This study assessed the attitudes and ethical considerations of patients and clinicians who participated in this trial. Methods Three mental healthcare institutions in secondary psychiatric care in the Netherlands participated in this study. Patients (n = 169), 18–65 years, diagnosed with schizophrenia, schizoaffective disorder or another psychotic disorder who had been prescribed antipsychotic depot medication, were randomly assigned to receive 12 months of either treatment as usual plus a financial reward for each depot of medication received (intervention group) or treatment as usual alone (control group). Structured questionnaires were administered after the 12-month intervention period. Data were available for 133 patients (69 control and 64 intervention) and for 97 clinicians. Results Patients (88%) and clinicians (81%) indicated that financial incentives were a good approach to improve medication adherence. Ethical concerns were categorized according to the four-principles approach (autonomy, beneficence, non-maleficence, and justice). Patients and clinicians alike mentioned various advantages of M4M in clinical practice, such as increased medication adherence and improved illness insight; but also disadvantages such as reduced intrinsic motivation, loss of autonomy and feelings of dependence. Conclusions Overall, patients evaluated financial incentives as an effective method of improving medication adherence and were willing to accept this reward during clinical treatment. Clinicians were also positive about the use of this intervention in daily practice. Ethical concerns are discussed in terms of patient autonomy, beneficence, non-maleficence and justice. We conclude that this intervention is ethically acceptable under certain conditions, and that further research is necessary to clarify issues of benefit, motivation and the preferred size and duration of the incentive. Trial registration Nederlands Trial Register, number NTR2350. Electronic supplementary material The online version of this article (10.1186/s12888-017-1485-x) contains supplementary material, which is available to authorized users.

Details

ISSN :
1471244X
Volume :
17
Database :
OpenAIRE
Journal :
BMC Psychiatry
Accession number :
edsair.doi.dedup.....2fcb6b8d8a51366784d0141c320b3107